The aim of this clinical trial is to investigate the concentrations of Lipocalin-2 and Semaphorin 3A levels in gingival crevicular fluid in subjects with different periodontal diseases. At the same time for the periodontitis group; the purpose of this study is to analyze the correlation of these proteins with clinical parameters at the first and third months after the nonsurgical periodontal treatment.

In our study, gingival crevicular fluid samples will be taken along with the measurement of all oral clinical parameters from sixty systemically healthy volunteers (20 periodontally healthy, 20 gingivitis, and 20 periodontitis). Gingival crevicular fluid samples will be taken again after the nonsurgical periodontal treatment for the periodontitis group in the first and third months. Lipocalin-2 and Semaphorin 3A levels will be determined by an enzyme-linked immunosorbent assay test (ELISA). Subsequent statistical analyses will be used to interpret protein levels among different groups and peridontitis group after the nonsurgical periodontal treatment.

Possible significant differences may illuminate the future work with Lipocalin-2 and Semaphorin 3A. Also, these glycoproteins may help to develop different diagnostic methods or treatment strategies for future periodontal treatments.

Inclusion Criteria:

• Being systemically healthy
• Having at least 20 teeth in the dentition, excluding third molars
• Not using alcohol nor smoking
• Not using medications
• Not taking any antibiotics, anti-inflammatory, nor systemic corticosteroid drugs in the last six months
• Not being in the lactation period nor pregnancy

Exclusion Criteria:

• Having any oral or systemic diseases
• Using alcohol or smoking
• Using medications
• Taking any antibiotics, anti-inflammatory, or systemic corticosteroid drugs in the last six months
• Being in the lactation period or pregnancy
• Being treated with periodontal treatment in the last six months